Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors
Recruiting now · Not applicable
Conditions studied: Sarcomas, Haematological Malignancies
In brief
The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients' diagnostic pathological material by histological, immunohistochemical, and molecular analysis; then, tumor markers will be sought in cryopreserved ovarian tissue.
Key facts
- Study ID
- NCT06829654
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- People needed
- 80
- Starts
- 2024-08-12
- Expected to finish
- 2026-08-12
- Last updated by the study team
- 2025-02-17
Who can join
Age: 18 and older, up to 38. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- For all groups:
- Patients with Ewing (ES) and synovial (SS) sarcoma, acute lymphoblastic leukemia (LLA), acute myeloid leukemia (LMA), chronic myeloid leukemia (LMC) and myelodysplasia (MDS)
- No objection to the procedure of sampling for cryopreservation or reimplantation of ovarian tissue by the patient's reference oncologist (according to PA105)
- Obtaining informed consent.
- Group 1:
- Age >18 and under 38 at the time of cryopreservation
- Request for cryopreservation of ovarian tissue at the Laboratory Cryopreservation Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO
- Group 2:
- Age >18 years
- Ovarian tissue already collected and cryopreserved at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO
- Group 3
- Age > 18 years
- Request for reimplantation of cryopreserved ovarian tissue at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures/Criobank IRCCS AOUBO
- Early menopause or menstrual irregularities
You may not qualify if…
- Group 1 and 3
- Contraindications to laparoscopy
- HIV, hepatitis B and C, treponema pallidum and positive PAP tests
- Malignant disease involving the ovary or samples to be reimplanted
- Group 2 None.
Where it is running
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.